重症急性呼吸器症候群(SARS)コロナウイルス感染症(SARS Coronavirus Infection)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview 8
Therapeutics Development 9
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Overview 9
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Comparative Analysis 10
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Therapeutics under Development by Companies 11
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Therapeutics under Investigation by Universities/Institutes 12
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Products under Development by Companies 15
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Products under Investigation by Universities/Institutes 16
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Companies Involved in Therapeutics Development 17
AlphaVax, Inc. 17
CEL-SCI Corporation 18
GeneCure LLC 19
Humabs BioMed SA 20
Kineta, Inc. 21
Myelo Therapeutics GmbH 22
Novavax, Inc. 23
Planet Biotechnology Inc. 24
Protein Sciences Corporation 25
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
CEL-1000 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
D-3252 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
EMER-IT – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
IKT-014 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ML-188 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MMCatLMC – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Monoclonal Antibodies for SARS Virus Infections – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Monoclonal Antibody for MERS and SARS – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Myelo-001 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rOAS – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SARS vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SARS vaccine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SARS Vaccine – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SARS-CoV Vaccine – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
severe acute respiratory syndrome vaccine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
severe acute respiratory syndrome vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule for SARS – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Synthetic Peptide to Target Spike Protein for SARS Infection – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
thiocarbazate – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vaccine for Respiratory and Infectious Diseases – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Recent Pipeline Updates 56
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Dormant Projects 57
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Discontinued Products 59
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Product Development Milestones 60
Featured News & Press Releases 60
May 19, 2014: Kineta’s Novel Antiviral Drugs Show Encouraging Efficacy Against Dengue And SARS Viruses 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62